| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | TAR-200 with Cetrelimab - (SunRISe-3) | BCG-naïve High-risk Non-muscle Invasive Bladder Cancer | Phase 3 | Intravesical | Oncology | |
| Johnson & Johnson | IMBRUVICA (ibrutinib) with Venetoclax - (SYMPATICO) | Mantle cell lymphoma | Phase 3 | Ongoing | Oral | Oncology |
| Johnson & Johnson | TREMFYA (guselkumab) - (GUIDE) | Plaque psoriasis | Phase 3 | Subcutaneous | Immunology: Anti-TNF | |
| Johnson & Johnson | Nipocalimab - (Vibrance-MG) | Generalized myasthenia gravis | Phase 2/3 | Data Released | Intravenous | Neurology |
| Johnson & Johnson | ARX788 (ACE-Gastric-02) | Gastric cancer | Phase 2/3 | Intravenous | Oncology | |
| Johnson & Johnson | Nipocalimab - (JASMINE) | Adults living with systemic lupus erythematosus (SLE) | Phase 2b | Data Released | Intravenous | Immunology |
| Johnson & Johnson | Posdinemab (JNJ-63733657) | Alzheimer's disease (AD) | Phase 2b | Ongoing | Intravenous | Neurology |
| Johnson & Johnson | TAR-200 with Cetrelimab - (SunRISe-4) | High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2b | Data Released | Intravesical | Oncology |